SavedAdd your journal

Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 3

Investigation of vancomycin resistance in methicillin-resistant Staphylococcus aureus

Metisiline dirençli Staphylococcus aureus kökenlerinde vankomisin direncinin araştırılması

Hoşgör Mine LİMONCU
Talay Banu SARIBAŞ
Pages
339–344
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, resistance to vancomycin in MRSA strains was not detected.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study was to investigate resistance to vancomycin in methiciliin-resistant Staphylococcus aureus (MRSA) strains.
📊
Key Findings & Data:Between 1998 and 2002,98 MRSA strains isolated from hospitalized patients at the Faculty of Medicine, Celal Bayar University, were studied.
💡
Conclusion & Impact:In conclusion, resistance to vancomycin in MRSA strains was not detected.
🔬Design:Research Article
📍Scope:2002 Verileri
⚙️Variables:Domain Parameters

Abstract

The purpose of this study was to investigate resistance to vancomycin in methiciliin-resistant Staphylococcus aureus (MRSA) strains. Between 1998 and 2002,98 MRSA strains isolated from hospitalized patients at the Faculty of Medicine, Celal Bayar University, were studied. Agar screening test was used to determine resistance to vancomycin of 98 MRSA strains and then minimum inhibition consantration (MIC) values for vancomycin of thece strains was investigated by agar dilution method. Agar plates containing 6 ug/mL vancomycin were used in agar screening test. No growth was observed in agar screening test. All 98 MRSA strains (100%) were found susceptible to vancomycin by agar dilution method. MIC50 and MIC90 values were 1 ug/mL and 2 ug/mL, respectively. The MIC range of the strains was determined as 0.25-2 ug/mL. In conclusion, resistance to vancomycin in MRSA strains was not detected.

Özet

Bu çalışmada metisiline dirençli Staphylococcus aureus (MRSA) kökenlerinde vankomisin direncinin araştırılması amaçlandı. Bunun için 1998-2002 tarihleri arasında Celal Bayar Üniversitesi Tıp Fakültesi Hastanesi'nde yatan hastalardan izole edilen 98 MRSA kökeni çalışmaya alındı. Doksan sekiz kökenin vankomisin direncini saptamak amacıyla agar tarama testi uygulandı. Bunun için 6 ug/mL vankomisin içeren agar plakları kullanıldı. Ardından kökenlerin agar dilüsyon yöntemiyle vankomisin için minimum inhibisyon konsantrasyon (MİK) değerleri belirlendi. Agar tarama testinde herhangi bir üreme gözlenmezken, agar dilüsyon testiyle 98 MRSA kökeninin %100'ü vankomisine duyarlı bulundu. Kökenlerin MİK50 değeri 1 ug/mL, MİK90 değeri 2 ug/mL ve MİK aralığı 0.25-2 ug/mL olarak saptandı. Bu çalışma sonucunda MRSA kökenlerinde vankomisin direnci saptanmadı.

🔖

Cite This Article

LİMONCU, H. M., SARIBAŞ, T. B. (2022). Investigation of vancomycin resistance in methicillin-resistant Staphylococcus aureus. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 3, 339–344. https://ajindex.com/articles/546479

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Kloos WE, Bannerman TL. Ştaphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. Washington DC: ASM Press, 1999: 264-82.
  2. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Ştaphylococcus aureus in a UK hospital. JAntimicrob Chemother 2QQV, 47: 399-403. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Ştaphylococcus aureus: comparative evaluation by the E test anda broth microdilution method. Diagn Microbiol Infect Dis 2002; 43: 319-21.
  3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin resistant Ştaphylococcus aureus clinical strain with reduced vancomycin susceptibility, j Antimicrob Chemother 1997; 40:135-6. 5. Aeschlimann JR, Hershberger E, Rybak MJ. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1914-8. 6. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3. 7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved Standard M7-A5. Villanova, PA: NCCLS, 2000. 8. Working Party of the British Society for Antimicrobial Chemotherapy. Breakpoints in in-vitro antibiotic susceptibility testing. J Antimicrob Chemother 1988; 21: 701-10. (Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-32.)' den alınmıştır. 9. Howden BP, Ward PB, Johnson PDR, Charles PGP, Grayson ML. Low-level vancomycin resistance in Staphylococcus aureus - an Australian perspective. EurJ Clin Microbiol Infect Dis 2005; 10.1007/10096-004-1261. 10. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann Rev Microbiol 2002; 56: 657- 75. 11. Yaygın YE. Metisilin dirençli Staphylococcus aureus kökenlerinde vankomisin direncinin araştırılması [Uzmanlık tezi], izmir: Ege Üniversitesi Tıp Fakültesi Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dalı, 2005. 12. Tenover FC, Biddl